Amgen Inc.


Want a discount? Become a member by purchasing Annual Subscription!
SKU: AMGN-1 Category:


Amgen experienced a decent quarter of growth, with total revenues up 4% and volume up 8%, reflecting strong global demand for many of their innovative medicines, such as Repatha and Prolia, as well as their biosimilar offerings. The development of multi-specific drugs to make untractable targets tractable is one of its primary research and molecular engineering interests. Teneobio’s acquisition, when combined with Nuevolution’s DNA encoded library technology, gives the company the ability to develop both large and small molecule multi-specifics. Besides, Amgen has started a Phase II study of LUMAKRAS monotherapy in patients with STK11 mutant and/or PD-L1 negative tumours in first-line non-small cell lung cancer. The management is also looking forward to tezepelumab, a first-in-class treatment for severe asthma that they aim to launch in the United States next year. This could be a significant growth driver for Amgen for years to come, given the millions of patients for whom existing asthma therapies are ineffective. We remain optimistic about Amgen’s future growth and maintain our ‘Hold’ rating on the stock with a revised target price.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!